- Home
- EDU vs LEGN Comparison
EDU vs LEGN Comparison
Compare EDU & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | LEGN |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 3.6B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EDU | LEGN |
|---|---|---|
| Price | $56.36 | $18.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $73.62 | $46.90 |
| AVG Volume (30 Days) | 398.8K | ★ 1.9M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.58 | $39.04 |
| Revenue Next Year | $12.33 | $25.29 |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.25 | $16.24 |
| 52 Week High | $64.97 | $37.50 |
Technical Indicators
Market Signals| Indicator | EDU | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 44.62 |
| Support Level | $54.06 | $16.98 |
| Resistance Level | $56.57 | $19.36 |
| Average True Range (ATR) | 1.05 | 0.81 |
| MACD | -0.09 | 0.19 |
| Stochastic Oscillator | 48.42 | 57.89 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in livestreaming e-commerce.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.